To date, early-phase trials evaluating the combination of olaparib with the pan-PI3K inhibitor buparlisib have demonstrated preliminary efficacy (ORR 30%) in patients with breast and ovarian cancer regardless of BRCA1/2-mutation status, although at the cost of adverse events such as mood disturbance requiring multiple dose reductions of buparlisib [45]. This evidence concerns the gene BRCA1 and ovarian carcinoma.